OS Therapies’ (NYSE:OSTX – Get Free Report) lock-up period is set to expire on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its initial public offering on August 1st. The ...

The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The ...

OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention of recurrent, fully resected, lung metastatic osteosarcoma. Results ...

On Friday, OS Therapies Inc (OSTX) stock saw a decline, ending the day at $2.95 which represents a decrease of $-1.17 or -28.40% from the prior close of $4.12. The stock opened at $4.09 and touched a ...

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line ...